Casiopeina III-ia: A Copper Compound with Potential Use for Treatment of Infections Caused by Leishmania mexicana.

IF 2 4区医学 Q3 ONCOLOGY Chemotherapy Pub Date : 2024-01-01 Epub Date: 2024-03-18 DOI:10.1159/000538360

José Delgado-Domínguez, Lizet Mejía-Camacho, Lisset Torres-Martínez, Jaime Zamora-Chimal, Rocely Cervantes-Sarabia, Adrián Espinoza-Guillen, Lena Ruiz-Azuara, Ingeborg Becker

{"title":"Casiopeina III-ia: A Copper Compound with Potential Use for Treatment of Infections Caused by Leishmania mexicana.","authors":"José Delgado-Domínguez, Lizet Mejía-Camacho, Lisset Torres-Martínez, Jaime Zamora-Chimal, Rocely Cervantes-Sarabia, Adrián Espinoza-Guillen, Lena Ruiz-Azuara, Ingeborg Becker","doi":"10.1159/000538360","DOIUrl":null,"url":null,"abstract":"Introduction: Casiopeina III-ia (CasIII-ia) is a mixed chelate copper (II) compound capable of interacting with free radicals generated in the respiratory chain through redox reactions, producing toxic reactive oxygen species (ROS) that compromise the viability of cancer cells, bacteria and protozoa. Due to its remarkable effect on protozoa, this study evaluated the effect of CasIII-ia on Leishmania mexicana amastigotes and its potential use as a treatment for cutaneous leishmaniasis in the murine model.Methods: We analyzed the leishmanicidal effect of CasIII-ia on L. mexicana amastigotes and on their survival in bone marrow-derived macrophages. Furthermore, we evaluated the production of ROS in treated parasites and the efficacy of CasIII-ia in the treatment of mice infected with L. mexicana.Results: Our results show that CasIII-ia reduces parasite viability in a dose-dependent manner that correlates with increased ROS production. A decrease in the size of footpad lesions and in parasite loads was observed in infected mice treated with the intraperitoneal administration of CasIII-ia.Conclusions: We propose CasIII-ia as a potential drug for the treatment of cutaneous leishmaniasis.","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373577/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538360","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Casiopeina III-ia (CasIII-ia) is a mixed chelate copper (II) compound capable of interacting with free radicals generated in the respiratory chain through redox reactions, producing toxic reactive oxygen species (ROS) that compromise the viability of cancer cells, bacteria and protozoa. Due to its remarkable effect on protozoa, this study evaluated the effect of CasIII-ia on Leishmania mexicana amastigotes and its potential use as a treatment for cutaneous leishmaniasis in the murine model.

Methods: We analyzed the leishmanicidal effect of CasIII-ia on L. mexicana amastigotes and on their survival in bone marrow-derived macrophages. Furthermore, we evaluated the production of ROS in treated parasites and the efficacy of CasIII-ia in the treatment of mice infected with L. mexicana.

Results: Our results show that CasIII-ia reduces parasite viability in a dose-dependent manner that correlates with increased ROS production. A decrease in the size of footpad lesions and in parasite loads was observed in infected mice treated with the intraperitoneal administration of CasIII-ia.

Conclusions: We propose CasIII-ia as a potential drug for the treatment of cutaneous leishmaniasis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Casiopeina III-ia：一种可用于治疗墨西哥利什曼原虫感染的铜化合物。

引言 Casiopeina III-ia（CasIII-ia）是一种混合螯合铜（II）化合物，能够与呼吸链中通过氧化还原反应产生的自由基相互作用，产生有毒的活性氧（ROS），从而损害癌细胞、细菌和原生动物的生存能力。由于 CasIII-ia 对原生动物的显著效果，本研究评估了 CasIII-ia 对墨西哥利什曼病（L. mexicana）变形虫的影响，以及在小鼠模型中用作皮肤利什曼病治疗的潜力。方法我们分析了 CasIII-ia 对墨西哥利什曼原虫的杀利什曼作用，以及对它们在骨髓衍生巨噬细胞中存活的作用。此外，我们还评估了处理过的寄生虫体内产生的 ROS 以及 CasIII-ia 治疗感染 L. mexicana 的小鼠的效果。结果我们的研究结果表明，CasIII-ia 能以剂量依赖的方式降低寄生虫的存活率，这与 ROS 的产生增加有关。腹腔注射 CasIII-ia 后，感染小鼠的脚垫病变面积和寄生虫数量均有所减少。结论我们建议将 CasIII-ia 作为治疗皮肤利什曼病的潜在药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Chemotherapy 医学-药学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamics properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.